Lifeward (LFWD) AI Stock Analysis

• Market Cap: $9.66M
• Dividend Yield: N/A
• Average Volume (3M): 289.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 4.96%
• EPS Growth: -13.09%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Devices
• EPS (TTM): -0.31
• Shares Outstanding: 15,704,622
• 10 Day Avg. Volume: 305,603
• 30 Day Avg. Volume: 289,148
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.23
• Enterprise Value/Revenue: 0.09
• Enterprise Value/Gross Profit: 0.26
• Enterprise Value/Ebitda: -0.14
• 1Y Price Target: $3.00
• Price Target Upside: 383.87% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 43 Neutral
• Price Target: ―

Lifeward's stock score is influenced by strong revenue growth but substantial risks due to profitability challenges, negative cash flows, and unattractive valuation. Technical indicators and recent corporate events further underscore the cautious outlook, despite strategic initiatives. Key risks involve financial instability and operational inefficiencies.

Positive Factors

Market Expansion

Management plans to expand market penetration of ReWalk Personal among patients covered by Centers for Medicare & Medicaid Services, workers compensation insurance and US commercial insurers.

Partnerships

Recent developments help diversify Lifeward's business through an exclusive partnership with CorLife and an expanded distribution agreement with MYOLYN.

Product Development

The company anticipates launching the next generation ReWalk 7.0, which could provide sustainable revenue growth in 2026 and beyond.

Negative Factors

Financial Performance

The company reported a net loss of $1.73 per share, compared to consensus estimated net loss of $0.31 per share.

Reimbursement Challenges

The company continues to experience longer than expected time to receive CMS reimbursement.

Revenue Guidance

Lifeward's FY2025 revenue guidance was mixed, showing lower revenue than forecasted despite a better bottom line.

Lifeward Business Overview & Revenue Model

Company Description

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

How the Company Makes Money

null

Lifeward Financial Statement Overview

Summary

Lifeward is experiencing strong revenue growth but faces significant profitability challenges. The company has a healthy balance sheet with a high equity ratio, though negative cash flows and earnings pose risks. Future improvements in operational efficiency are crucial for financial sustainability.

Income Statement

Lifeward's revenue has shown strong growth, from $4.4 million in 2020 to $25.7 million in 2024, marking a significant upward trajectory. However, the company has consistently posted negative EBIT and net income, indicating operational inefficiencies and challenges in achieving profitability. The gross profit margin is improving but remains offset by high operating expenses.

Balance Sheet

The company has a healthy stockholders' equity position, which is significantly higher than its total liabilities, resulting in a low debt-to-equity ratio. However, the return on equity is negative due to consistent net losses, highlighting a risk of financial instability despite the strong equity base.

Cash Flow

Lifeward experiences negative operating and free cash flow, indicating reliance on external financing for operations. The free cash flow growth rate is negative, showing challenges in converting revenue to cash. Cash flow ratios to net income are unfavorable, reflecting operational cash deficits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	24.43M	25.66M	13.85M	5.51M	5.97M	4.39M
Gross Profit	8.70M	8.22M	4.45M	1.91M	2.90M	2.19M
EBITDA	-16.19M	-24.93M	-21.77M	-18.90M	-12.39M	-11.73M
Net Income	-29.76M	-28.94M	-22.13M	-19.57M	-12.74M	-12.98M
Balance Sheet
Total Assets	26.78M	30.49M	63.19M	74.24M	94.75M	28.07M
Cash, Cash Equivalents and Short-Term Investments	5.14M	6.75M	28.08M	67.90M	88.34M	20.35M
Total Debt	375.00K	880.00K	1.90M	897.00K	1.06M	1.58M
Total Liabilities	11.67M	11.64M	16.68M	6.07M	5.37M	6.29M
Stockholders Equity	15.11M	18.85M	46.51M	68.17M	89.38M	21.77M
Cash Flow
Free Cash Flow	-17.86M	-21.72M	-20.75M	-17.92M	-11.52M	-12.66M
Operating Cash Flow	-17.86M	-21.72M	-20.67M	-17.89M	-11.47M	-12.59M
Investing Cash Flow	18.14M	0.00	-18.15M	-25.00K	-47.00K	-73.00K
Financing Cash Flow	2.07M	0.00	-992.00K	-2.50M	79.51M	16.72M

Lifeward Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Negative. The current price of 0.62 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.76, and below the 200-day MA of 1.43, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.13 is Neutral, neither overbought nor oversold. The STOCH value of 17.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFWD.

Lifeward Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	kr6.20B	8.14	-27.68%	2.18%	27.02%	14.83%
PAVM	51 Neutral	$8.10M	0.40	-499.57%	―	-73.36%	―
BMRA	49 Neutral	$8.68M	―	-72.70%	―	5.05%	26.13%
XAIR	49 Neutral	$10.77M	―	-323.27%	―	168.20%	63.41%
CODX	45 Neutral	$12.29M	―	-63.40%	―	-91.14%	9.47%
LFWD	43 Neutral	$9.66M	―	-114.90%	―	4.96%	-13.09%
DHAI	41 Neutral	$13.51M	―	9.26%	―	―	―

Lifeward Corporate Events

Lifeward Announces Termination of Chief Sales Officer

Lifeward has announced that Charles Remsberg’s role as Chief Sales Officer will be terminated without cause, effective May 30, 2025. This decision, disclosed in the company’s annual report, ensures Mr. Remsberg will receive severance and benefits as per his employment agreement, potentially impacting the company’s sales leadership and strategy.

Spark’s Take on LFWD Stock

According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral.

Lifeward’s stock is rated low primarily due to ongoing financial challenges, despite strong revenue growth. Technical indicators suggest a current downtrend, and valuation metrics are unattractive due to negative earnings. While strategic initiatives show promise, the high risks associated with financial instability and operational inefficiencies are significant concerns.

To see Spark’s full report on LFWD stock, click here.

Rewalk Robotics CEO Larry Jasinski to Step Down

On February 19, 2025, Rewalk Robotics announced that Larry Jasinski will step down as CEO and board member by the end of the second quarter of 2025. Jasinski’s departure will be considered a termination without cause, and the company plans to finalize a separation agreement with him before his exit.